An Infant with 49XXXXY Syndrome; A case report from Sri Lanka

Atapattu N1, Liyanage C2, Naotunna C3
1Endocrinology and Diabetic Unit, Lady Ridgeway Hospital, Colombo
2Paediatric unit, Provincial General Hospital, Badulla

INTRODUCTION

49XXXXY Syndrome is a rare chromosomal aneuploidy with few hundred case reports published all over the world. The classic triad of symptoms includes mental retardation, hypogonadism and radioulnar synostosis with several other congenital malformations, associated medical conditions and psychological impact.

To the best of our knowledge it has never been reported in Sri Lanka previously.

PRESENTING CONCERNS

This, day 10 old neonate who was born in a tertiary care center was referred due to detection of ambiguous genitalia at birth. He was the 1st child born to healthy non consanguineous Tamil parents from Badulla district. At the time of conception mother was 31 years and she had an uneventful antenatal period with normal antenatal scans except for a low estimated foetal weight.

He was born at term via normal vaginal delivery with a birth weight of 2.385kg, length 47 cm and OFC 32cm. APGAR score at birth was 1<sup>st</sup> 5<sup>th</sup> 10<sup>th</sup>.

No documented evidences of neonatal hypoglycaemia and baby didn’t have jaundice. During the hospital stay baby was well fed and his serum electrolyte levels, serum calcium levels remained normal throughout.

CLINICAL FINDINGS

On day 10 of examination
- body weight: 2.190kg (8% weight loss)
- length: 48cm
- OFC: 32 cm
- Hypertelorism
- Upplanting palpebral fissures
- Flat occiput
- Mild webbing of neck
- No midline defects
- No generalized pigmentation of body
- System examination: normal
- Genitalia examination: bifid scrotum

INVESTIGATIONS

- Serum Electrolytes: Normal
- Thyroid function tests: Normal
- DHEAS: 1.26mmol/L level (normal)
- Serum testosterone: 6.3nmol/L level (normal)
- 17-OHP: 12.352nmol/L level (normal)
- Serum FSH level: 22.59 IU/L (elevated)
- Serum LH level: 12.69 IU/L (normal)
- Ultrasound abdomen,scrotum: normal adrenal glands, no persistent Mullerian structures
- X-ray forearm and wrist: no radiological evidences of radio ulnar synostosis
- Karyotype: chromosomal aneuploidy of 49XXXXY syndrome
- 2D echocardiogram: an insignificantly small patent foramen ovale with otherwise normal heart

DISCUSSION

In 1960 Fraccaro et al reported the first case of 49XXXXY Syndrome. It is the rarest X chromosome aneuploidy with an approximate incidence of 1: 85,000 – 100,000 male births. Non-disjunction of X chromosomes during both meiosis I and II is the probable chromosomal anomaly leading to 49XXXXY syndrome.

Initially this was considered as a variant of Klinefelter syndrome, but the prevalence of moderate to severe mental retardation with a low Intelligence Quotient and multiple associated malformations in 49XXXXY syndrome demarcates the differences between these 2 clinical entities.

The classic triad of symptoms include mental retardation, hypogonadism and radioulnar synostosis though our patient did not have the latter finding. Other clinical manifestations include microcephaly with short stature, distinct facial features such as round face, ocular hypertelorism, upplanting palpebral fissures and flat nasal bridge, cleft palate, musculoskeletal defects such as genu valgum, pes cavus or planus, clinodactyly, scoliosis, hip dysplasia and hypotonia, congenital heart defects; patent ductus arteriosus being the commonest; and delayed neurocognitive development with low IQ levels. Also they are more susceptible to infections and immunodeficiency.

Only one case reported the presence of diabetes in an 18 year old 49XXXXY patient though diabetes is common among Klinefelter syndrome.

Behavioural and development aspects in view of 49XXXXY has been studied widely with several other congenital malformations, associated medical conditions and psychological impact. Our presenting child already had speech delay and he needs further follow up for assessment.

Hypergonadotrophic hypogonadism needs to be evaluated at the age of puberty and hormone replacement therapy with IM testosterone should be initiated granting endocrinology follow up.

REFERENCES